Biosensor offers safer and more reliable detection method as an
alternative to animal toxicity testing.
MONTREAL, June 27 /CNW Telbec/ - (TSX-V: BUG) Biophage Pharma Inc.
(Biophage) is very pleased to announce that the PDS(R) Biosensor will make its
commercial debut today at the Nanotoxicity 2007 Trade show in Paris, France.
This product represents the first of many innovative biosensors in development
by our Biosensor Division. Biophage President and CEO, Dr. Mandeville, will
make a presentation on the PDS(R) technology platform and the targeted markets
for this biosensor, which was designed for the rapid detection of toxicity
(predictive toxicity) of metals and nanoparticles.
The global demand for biosensors capable of rapidly detecting the toxic
effect of metals or nanoparticles on living human cells is exploding.
According to a recent BBC technical market research report, the U.S. in vitro
toxicity testing (predictive toxicity) market had a value of $765 million in
2006 and will double by 2011, reaching $1.5 billion. Biophage is well
positioned to capitalize on this rapidly expanding market by offering
companies and research laboratories a novel and efficient biosensor that can
rapidly screen large numbers of compounds for cell toxicity.
The PDS(R) Biosensor allows for the rapid and simultaneous screening of a
large number of toxic compounds, metals and nanoparticles and determines their
relative level of toxicity. It can also identify important parameters that
determine toxicity levels at various stages of development and manufacturing,
allowing companies to explore different strategies to circumvent potential
toxic effects or mitigate the risk to humans, animals and the environment. Our
targeted clients are government and regulatory agencies, research laboratories
and environmental investigators in the biopharmaceutical, agricultural,
cosmetics and probiotics fields.
"After many years of research and development, we are extremely pleased
to have reached this important commercial milestone. I would like to
congratulate our PDS(R) Biosensor development team who worked tirelessly to
achieve our projected 2007 Q2 completion date, particularly Dr. Béatrice
Allain (R&D Director)." stated Dr. Rosemonde Mandeville, President and CEO of
Biophage Pharma Inc. "This versatile biosensor provides a user friendly, rapid
and safer in vitro toxicological first screening detection method. It
represents a viable, cost effective alternative for toxicity testing and at
the same time offers customers a "politically correct" solution which
addresses the controversial issue of animal testing." continued Dr Mandeville.
About Biophage Pharma Inc.
Biophage Pharma is a high potential, revenue-driven Canadian
biotechnology company focused on the development of innovative phage-based
products and technologies for the detection, prevention and control of
bacterial infections. Founded in 1995, Biophage operates three divisions: (1)
The Biosensors division for the development and commercialization of
Biosensors, more particularly the PDS(R) Biosensor; (2) The phage therapy
division for the prevention and control of bacterial contaminations in the
medical, veterinary and environment fields; (3) The Immunotox Labs division,
which provides services in Immunogenicity and Immunotoxicity, Beryllium
sensitivity testing and MELISA(R) testing for the detection of sensitization
to more than 200 different allergens including metals, penicillin, gluten,
pollens and more recently Lyme disease (Boreliosis). (www.biophagepharma.net;
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
For further information:
For further information: Biophage Pharma Inc.: Rosemonde Mandeville,
M.B., Ch.B., PhD., President and CEO, (514) 496-1488,
email@example.com; Louis Guindon, Chief Financial
officer, (514) 496-3230, firstname.lastname@example.org; Renmark Financial
Communications Inc.: Christine Stewart: email@example.com;
Philippe DeSerres: firstname.lastname@example.org, (514) 939-3989, Fax: (514)